Sarepta Therapeutics (SRPT) Continues Run as Eteplirsen Sentiment Remains High
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Sarepta Therapeutics (SRPT) Riding High On Successful Drug
August 30, 2012 8:08 AM EDTSarepta Therapeutics, Inc. (Nasdaq: SRPT) is higher yet again in pre-open trading Thursday as the company's Duchenne Muscular Dystrophy treatment continues to get positive, tear-jerking press.
Yesterday evening,... More
Sarepta Therapeutics (SRPT) Higher on Barron's Mention
August 27, 2012 9:05 AM EDTSarepta Therapeutics (Nasdaq: SRPT) continues its recent ramp following a positive piece in Barron's over the weekend highlighting the company's treatment for Duchenne muscular dystrophy.
While shares are up from $4 to $10 recently, analysts argue they could go as high as $26 as peak sales of... More
